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Moriarty et al Alirocumab in statin-intolerant patients 75924 weeks. Alirocumab dose was increased to 150 mg Q2W at week 12 depending on week 8 LDL-C
values. Primary end point was percent change in LDL-C from baseline to week 24 (intent-to-treat) for
alirocumab vs ezetimibe.
RESULTS: Baseline mean (standard deviation) LDL-C was 191.3 (69.3) mg/dL (5.0 [1.8] mmol/L).
Alirocumab reduced mean (standard error) LDL-C by 45.0% (2.2%) vs 14.6% (2.2%) with ezetimibe
(mean difference 30.4% [3.1%], P , .0001). Skeletal muscle-related events were less frequent with
alirocumab vs atorvastatin (hazard ratio 0.61, 95% confidence interval 0.38–0.99, P 5 .042).
CONCLUSIONS: Alirocumab produced greater LDL-C reductions than ezetimibe in statin-intolerant
patients, with fewer skeletal-muscle adverse events vs atorvastatin.
 2015 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Statins are the treatment of choice for lowering low-density
lipoprotein cholesterol (LDL-C),1,2 producing substantial re-
ductions in cardiovascular morbidity andmortality in primary
and secondary prevention.3 Statins are generally well toler-
ated, and serious side effects are rare.4 However, many pa-
tients may suffer statin-associated muscle symptoms and are
unable to either take any dose or increase the dose sufficiently,
even after trying an alternate statin, to achieve long-term
reduction of LDL-C and cardiovascular risk.4–7
Statin-associated muscle symptoms encompass a wide
range of clinical presentations.8 Symptoms are subjective
and, in the absence of a definitive diagnostic test, the prev-
alence remains unclear.8 In a meta-analysis of 26 random-
ized trials, approximately 13% of statin-treated patients
reported muscle complaints, most commonly myalgia.9
This is most likely an underestimate because patients with
a history of, or at an increased risk of, intolerance were
excluded from many of the trials in this meta-analysis.
Observational data suggest a prevalence ranging from 7%
to 29%.5,8 The Effect of Statins on Skeletal Muscle Function
and Performance trial investigated the rate of statin intoler-
ance in healthy statin-na€ıve patients. Overall, muscle com-
plaints occurred in 9.4% of patients on atorvastatin 80 mg
vs 4.6% on placebo (P 5 .05), indicating an approximate
5% rate of muscle events with high-dose statin.10
Large, well-controlled randomized trials of cholesterol-
lowering drugs in statin-intolerant patients are lacking, and
there remains a need for an effective non-statin treatment
for patients who are intolerant of these medications and
remain at cardiovascular risk. Alirocumab is a fully human
monoclonal antibody against proprotein convertase subtil-
isin kexin type 9. Alirocumab reduced LDL-C concentra-
tions by 40% to 70% when given in combination with other
lipid-lowering therapies or as monotherapy.11–19 The
ODYSSEY ALTERNATIVE study compared the reduction
of LDL-C produced by alirocumab vs ezetimibe after
24 weeks of treatment in patients with primary hypercho-
lesterolemia and well-documented statin intolerance. The
study included a placebo run-in period before randomiza-
tion, during which patients who developed musclesymptoms in the absence of statin exposure were excluded
from continuing in the trial. Ezetimibe was selected as the
active control as it is a recommended option for LDL-C
lowering in statin-intolerant patients due to a favorable
safety profile.20 The trial also sought to determine safety
compared with atorvastatin in an at-risk population that
had failed multiple attempts to use first-line evidence-based
statin therapy. Thus, a blinded statin rechallenge arm was
conducted in parallel with blinded alirocumab and ezeti-
mibe arms. An optional open-label treatment period on alir-
ocumab continued after 24 weeks of double-blind
treatment.Materials and methods
Study design
ODYSSEYALTERNATIVE (NCT01709513) was a ran-
domized, double-blind, double-dummy, active-controlled,
parallel-group study conducted at 67 sites in 8 countries
(Austria, Canada, France, Israel, Italy, Norway, the UK, and
the USA), with enrollment from November 2012 to October
2013. The study rationale andmethods have been published.21
The study was conducted according to the Declaration of
Helsinki and the International Conference on Harmonisation
Guidelines for Good Clinical Practice. The institutional
review board and ethics committee at each center approved
the protocol; all participants gave written informed consent.
Study population
The population comprised patients ($18 years) with
primary hypercholesterolemia.21 Patients at moderate or
high cardiovascular risk (as defined in Supplemental Text 2)
were eligible if they had a calculated serumLDL-Cconcentra-
tion $ 100 mg/dL (2.6 mmol/L) at screening; those at very
high risk were eligible if they had a calculated serum LDL-
C$70mg/dL (1.8mmol/L).21 During screening, each patient
completed a questionnaire that collected data on history of
statin therapies and symptoms. Statin intolerancewas defined
as the inability to tolerate 2 or more statins because of
760 Journal of Clinical Lipidology, Vol 9, No 6, December 2015unexplained skeletal muscle–related symptoms (eg, pain,
aches, weakness, or cramping), other than those due to strain
or trauma that began or increased during statin treatment and
resolved with statin discontinuation (see Supplemental
Text 2). One of the 2 statins had to have been discontinued
while at or below the lowest-approved daily starting dose
(ie, rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin
10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin
40 mg, pitavastatin 2 mg). A full list of the exclusion criteria
is available.21
Intervention
The study comprised 5 periods: 1-week screening; 2-
week washout of ezetimibe, statins (for patients taking a
less than lowest-approved daily starting dose or regimen),
and red yeast rice; 4-week single-blind placebo run-in to
exclude patients with non-statin–related muscle symptoms;
24-week double-blind treatment; and 8-week off-treatment
follow-up.21 See Supplemental Text 2 for details on diet
and use of non-statin medications. As an alternative to
the 8-week follow-up, patients who successfully completed
the double-blind treatment period or discontinued due to a
muscle-related adverse event (AE) were offered up to
196 weeks of alirocumab in an open-label treatment period,
starting at their planned week 24 visit.
Patients who completed the placebo run-in without
experiencing a skeletal muscle–related AE were randomized
to alirocumab, ezetimibe, or atorvastatin (2:2:1, respectively,
permuted block design), with stratification for history of
myocardial infarction or ischemic stroke, to receive subcu-
taneous (SC) alirocumab 75 mg twice weekly (Q2W) and
oral placebo for ezetimibe or atorvastatin daily, or SC
placebo Q2W for alirocumab and either oral ezetimibe
10 mg daily or atorvastatin 20 mg daily (statin rechallenge
arm). Oral and SC medications were blinded.21 At week 12
of the 24-week double-blind treatment period, the alirocu-
mab dose was increased to 150 mg Q2W (also in a 1-mL
volume) if the patient’s week 8 LDL-C concentration re-
mained elevated ($70 mg/dL [1.8 mmol/L] in very high car-
diovascular risk patients or $100 mg/dL [2.6 mmol/L] in
moderate or high cardiovascular risk patients).
After 24 weeks, all eligible patients could enter the
open-label treatment phase of the study and continue
alirocumab 75 mg SC Q2W for approximately 3 years
(see Supplemental Text 2).
Efficacy outcome measures
The primary efficacy end point was the percent change
in calculated LDL-C concentration from baseline to week
24 by intent-to-treat (ITT) approach. Key secondary
efficacy end points were changed from baseline to 24 weeks
using on-treatment (modified ITT) LDL-C values, and
percent change from baseline to 12 and 24 weeks in
LDL-C, apolipoprotein B, non–high-density lipoprotein
cholesterol (non–HDL-C), total cholesterol, lipoprotein(a),HDL-C, apolipoprotein A1, and fasting triglyceride con-
centrations. All efficacy end points were assessed for
alirocumab vs ezetimibe arms (see Supplemental Text 2).
Efficacy comparisons vs atorvastatin were not assessed as
this treatment arm was only included as an essential control
to define the appropriate patient population.
Safety outcome measures
Safety end points included AEs, irrespective of their
possible relationship to the study drug, defined as those that
developed, worsened, or became serious during each of the
3 phases of the study: pretreatment, double blind, and open
label. All AEs were assessed by both patient self-reports
and AE query. Skeletal muscle AEs included a predefined
category of AEs (comprising myalgia or myositis, muscle
spasms, muscular weakness, musculoskeletal stiffness, and
muscle fatigue) that were identified, on the basis of expert
opinion, to be closely related to statin intolerance (see
Supplemental Text 2).
Statistical analysis
A sample of 42 patients in both the alirocumab and
ezetimibe treatment groups would provide 95% power to
detect a 20% difference between alirocumab and ezetimibe
in least squares (LS) mean percent change from baseline
to week 24 in LDL-C, using a 2-sided t-test and assuming
a common standard deviation (SD) of 25%.11 The over-
all study sample size for safety parameters during the
double-blind treatment period was planned to be 250 pa-
tients, allocating 100 patients to both the alirocumab and
ezetimibe arms and 50 patients to the statin arm. With spe-
cific attention to study treatment withdrawal due to AEs,
100 patients in both the alirocumab and ezetimibe arms
would give a 96% probability of recording at least 1 with-
drawal event assuming that the event occurs in approxi-
mately 3.3% of the population for each arm, based on
product information.22
The ITT analysis used for evaluation of the primary end
point included all calculated LDL-C values, irrespective of
treatment adherence, up to week 24. Missing data were
accounted for using a mixed-effect model with repeated
measures approach.23,24 The consistency of the treatment ef-
fect for the primary end point was assessed across prespeci-
fied subgroups.21 A P value of #.05 was considered to be
statistically significant.
A hierarchical testing procedure was used to control
type I error and handle multiplicity for analyzing the key
secondary end points.21 The first secondary end point was
an on-treatment (modified ITT) analysis. Further second-
ary end points, in order of hierarchical testing, included
percent change in LDL-C from baseline to week 12
(ITT and on-treatment), the percent change in other lipid
parameters, and the proportion of patients reaching their
cardiovascular-risk-based LDL-C goal at week 24 in
both the ITT and on-treatment analyses (see also
Moriarty et al Alirocumab in statin-intolerant patients 761Supplemental Table 1). The modified ITT population
included all randomized and treated patients with a base-
line LDL-C measurement and at least 1 measurement af-
ter 4 to 24 weeks of treatment, as long as the patient was
on study treatment. For this analysis, all available mea-
surements from weeks 4 to 24 within the on-treatment
time window were used in the mixed-effect model with
repeated measures model. Binary efficacy end points
were analyzed using the multiple imputation approach
followed by logistic regression; continuous efficacy end
points anticipated to have a non-normal distribution (ie,
triglycerides and lipoprotein[a]) were analyzed using the
same multiple imputation approach followed by robust
regression. The analysis was performed using SAS
version 9.2 software.Figure 1 Flow chart. IResults
Patients and intervention
Of the 519 patients screened, 361 met the eligibility
criteria (and entered the placebo run-in), and 314 (87.0%)
completed the placebo run-in and were randomized to 1 of
the 3 treatment arms: 126 to alirocumab, 125 to ezetimibe,
and 63 to atorvastatin (Fig. 1). Of the 47 patients who failed
to complete the placebo run-in, 25 had skeletal muscle–
related symptoms as defined by exclusion criteria, and 23
of 47 (48.9%) had at least 1 skeletal muscle–related AE ac-
cording to a predefined category of AEs, of which the most
common was myalgia (9 of 47; 19.1%) and muscle spasmsTT, intent-to-treat.
Table 1 Characteristics by randomized treatment*
Characteristic Alirocumab† (n 5 126) Ezetimibe‡ (n 5 125) Atorvastatinx (n 5 63)
Age, mean (SD), y 64.1 (9.0) 62.8 (10.1) 63.4 (8.9)
Male gender, n (%) 70 (55.6) 67 (53.6) 35 (55.6)
Race, n (%)k
White 117 (92.9) 116 (92.8) 62 (98.4)
Black or African American 5 (4.0) 7 (5.6) 0
Other 4 (3.2) 2 (1.6) 1 (1.6)
Body mass index, mean (SD), kg/m2 29.6 (6.6) 28.4 (4.9) 29.7 (5.4)
HbA1c, mean (SD), % 5.86 (0.66) 5.73 (0.55) 5.87 (0.72)
Creatine kinase, mean (SD), ULN 0.7 (0.5) 0.7 (0.4) 0.8 (0.6)
Current smoker, n (%) 11 (8.7) 5 (4.0) 5 (7.9)
Selected medical history, n (%)
Abdominal aortic aneurysm 3 (2.4) 2 (1.6) 3 (4.8)
Acute myocardial infarction 21 (16.7) 15 (12.0) 7 (11.1)
Carotid artery occlusion .50% without symptoms 10 (7.9) 6 (4.8) 6 (9.5)
Carotid endarterectomy or carotid artery stent procedure 6 (4.8) 3 (2.4) 2 (3.2)
Chronic kidney disease (eGFR 30–,60 mL/min/1.73 m2) 6 (4.8) 8 (6.4) 2 (3.2)
Coronary heart disease 64 (50.8) 54 (43.2) 28 (44.4)
Diabetes mellitus (type 2) 36 (28.6) 24 (19.2) 15 (23.8)
Hypertension 85 (67.5) 77 (61.6) 35 (55.6)
Ischemic stroke 4 (3.2) 5 (4.0) 5 (7.9)
Transient ischemic attack 9 (7.1) 7 (5.6) 4 (6.3)
Peripheral artery disease 1 (0.8) 2 (1.6) 3 (4.8)
Renal artery stenosis or renal artery stent procedure 0 2 (1.6) 0
Cardiovascular risk level
Moderate{ 19 (15.1) 14 (11.2) 10 (15.9)
High# 29 (23.0) 47 (37.6) 13 (20.6)
Very high** 73 (57.9) 62 (49.6) 35 (55.6)
Lipid parameters, mean (SD) or median (quartile 1, quartile 3)
LDL-C (Friedewald formula), mg/dL 191.1 (72.7) 193.5 (70.9) 187.3 (59.5)
Range (min:max) 91:577 81:427 86:382
LDL-C (beta-quantification method), mg/dL 179.4 (71.3) 188.1 (72.7) 181.8 (60.9)
Min:max 99:584 87:443 76:370
Apolipoprotein B, g/L 141.7 (39.5) 138.2 (37.4) 139.1 (34.7)
Total cholesterol, mg/dL 278.9 (79.5) 280.5 (83.3) 274.9 (63.2)
Non–HDL-C, mg/dL 230.0 (80.4) 229.8 (82.7) 223.8 (64.8)
Lipoprotein(a), mg/dL 18.0 (8.0, 47.0) 14.0 (7.0, 43.0) 12.0 (6.0, 50.0)
Triglycerides (fasting), mg/dL 164.0 (114.0, 233.0) 140.0 (95.0, 218.0) 158.0 (119.0, 246.0)
HDL-C, mg/dL 48.9 (15.3) 50.7 (14.1) 51.1 (12.5)
Apolipoprotein A1, mg/dL 149.4 (25.0) 150.0 (24.2) 154.2 (24.8)
LMT (other than statin) at randomization, n (%) 47 (37.3) 55 (44.0) 34 (54.0)
LMT (other than nutraceutical) at randomization, n (%) 41 (32.5) 48 (38.4) 31 (49.2)
Nutraceutical 7 (5.6) 17 (13.6) 6 (9.5)
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Moriarty et al Alirocumab in statin-intolerant patients 763(7 of 47; 14.9%) (Supplemental Table 2). Others excluded
from entering the double-blind treatment period did so for
reasons such as withdrawal of consent and unstable dose
of concomitant medicine.
Patient baseline characteristics and lipid parameters
were evenly distributed across the study arms (Table 1).
Overall mean (SD) age was 63.4 (9.5) years, 54.8% were
men, 93.9% were white, and mean (SD) baseline LDL-C
was 191.3 (69.3) mg/dL (range 81.0–577.0 mg/dL; 5.0
[1.8] mmol/L, range 2.1–14.9 mmol/L). Rates of coronary
heart disease and cardiovascular risk factors were high.
All patients with known data had reported the development
of muscle symptoms since starting the most recent statin
therapy before entering the study (Supplemental Table 3).
In most cases, symptoms were new, bilateral, and constant.
During the double-blind treatment period, 141 (45.0%)
patients received lipid-modifying therapy with bile acid
sequestrants, nicotinic acid, fenofibrate, or omega-3 fatty
acids (Table 1). In this population of patients with very high
baseline LDL-C, half of the patients (n 5 54, 49.5%) in the
alirocumab arm required a dose increase from 75 to 150 mg
Q2W per protocol.
Ninety-six (76.2%) patients in the alirocumab arm, 82
(65.6%) in the ezetimibe arm, and 42 (66.7%) in the
atorvastatin arm remained on treatment throughout the
double-blind treatment period (Fig. 1). The primary reason
for treatment discontinuation was the occurrence of an AE.
A total of 281 patients (89.5% of those randomized) who
completed the double-blind period entered the ongoing
open-label treatment period with alirocumab, 117 of 126
(92.9%) from the alirocumab arm, 105 of 124 (84.7%)
from the ezetimibe arm, and 59 of 63 (93.7%) from the
atorvastatin arm.
Efficacy
For the primary ITT efficacy analysis, LS mean (stan-
dard error [SE]) change in LDL-C concentrations from
baseline to week 24 were 245.0% (2.2%) for alirocumab
and 214.6% (2.2%) for ezetimibe, with a difference
between groups of 230.4% (3.1%; P , .0001). For the
on-treatment analysis, the LS mean (SE) change from base-
line was 252.2% (2.0%) for alirocumab and 217.1%
(2.0%) for ezetimibe (LS mean difference of 235.1%
[2.8%], P , .0001). A substantial reduction in LDL-C con-
centration occurred over the first 4 weeks, which was
greater in the alirocumab arm (Fig. 2) and persisted
throughout the 24-week treatment period. The on-
treatment values demonstrate a durable treatment effect.
The distribution of baseline and achieved LDL-C values
for alirocumab and ezetimibe at 24 weeks is shown in
Figure 3. At week 24, 52 (41.9%) patients on alirocumab
and 5 (4.4%) of those on ezetimibe (P , .0001; ITT anal-
ysis) reached an LDL-C goal of ,70 mg/dL (1.8 mmol/
L) in very high cardiovascular risk patients or ,100 mg/
dL (,2.6 mmol/L) in moderate-to-high-risk patients. Cor-
responding results in the on-treatment population were
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Figure 2 LDL-C concentrations vs study time points (on-treat-
ment analysis using raw data). Values at week 12 and week 24
data points indicate achieved LDL-C concentration and LS mean
(SE) percent change from baseline. In a post-hoc ITT analysis,
the mean (SD) change in LDL-C concentration in the atorvastatin
arm was 231.9% (25.1%) at week 24. ITT, intent-to-treat;
LDL-C, low-density lipoprotein cholesterol; LS, least squares;
Pts, patients; SD, standard deviation; SE, standard error.
764 Journal of Clinical Lipidology, Vol 9, No 6, December 201551.2% and 5.6% (P , .0001). The greater effect of alirocu-
mab relative to ezetimibe on LDL-C-lowering from
baseline to week 24 was consistent across most of the pre-
specified subgroups in the ITT population (Supplemental
Fig. 1). In addition, reductions in apolipoprotein B, non–
HDL-C, total cholesterol and lipoprotein(a) concentrations
were greater for alirocumab vs ezetimibe (all P , .0001;
Table 2). There were no statistically significant differencesFigure 3 Distribution by 10-mg/dL increments of LDL-C concentratio
ezetimibe (right panel; modified ITT population using raw data). Compa
as 24-week data were not available for all patients. ITT, intent-to-treat; L
SE, standard error.between the 2 groups in changes in triglyceride, HDL-C,
and apolipoprotein A1 concentrations.
Safety and tolerability
Overall rates of treatment-emergent and serious AEs
were generally similar between treatment arms, and there
were no deaths in the study (Table 3). Discontinuations due
to treatment-emergent AEs trended lower in the alirocumab
treatment arm. Myalgia was the most common AE in all
groups. Muscle spasms occurred in 4.0% of alirocumab pa-
tients vs 7.3% of ezetimibe patients and 11.1% of atorvas-
tatin patients. One case of myositis occurred in the
atorvastatin arm. The rate of skeletal muscle–related AEs
was significantly lower with alirocumab vs atorvastatin
(hazard ratio [HR] 0.61, 95% confidence interval (CI)
0.38 to 0.99, P5 .042; Fig. 4). A similar trend was observed
for alirocumab vs ezetimibe (HR 0.71, 95% CI 0.47–1.06,
P 5 .096), but it did not reach statistical significance. The
difference in the rate of skeletal muscle–related AEs was
seen soon after study drug initiation (Fig. 4). The rate of
study treatment discontinuation due to skeletal muscle–
related AEs was nonsignificantly different for alirocumab
vs atorvastatin (HR 0.67, 95% CI 0.34–1.32, P 5 .24) or
ezetimibe (HR 0.78, 95% CI 0.43–1.41, P 5 .41).
Treatment-emergent AEs that occurred in $2% of any
treatment group are detailed in Supplemental Table 4.
Briefly, those occurring in $5% of patients were myalgia
(24.6%), nasopharyngitis (6.3%), upper respiratory tract
infection (5.6%), and arthralgia (5.6%) in the alirocumabn at baseline and week 24 in patients on alirocumab (left panel) or
rison between week 24 and baseline is descriptive and exploratory,
DL-C, low-density lipoprotein cholesterol; SD, standard deviation;
Table 2 Percent change from baseline in LDL-C and in selected key secondary lipid parameters in prespecified hierarchical testing
order
End point Alirocumab* Ezetimibe†
Alirocumab* vs ezetimibe†
LS mean
difference
(SE), % 95% CI P value
Primary end point: LDL-C (baseline–wk 24, ITT) n 5 126 n 5 122
Baseline LDL-C, mean (SD), mg/dL 191.1 (72.7) 194.2 (71.2) — — —
LS mean (SE) change from baseline, % 245.0 (2.2) 214.6 (2.2) 230.4 (3.1) 236.6 to 224.2 ,.0001
First key secondary end point: LDL-C
(baseline to wk 24, on treatment)
n 5 123 n 5 118
Baseline LDL-C, mean (SD), mg/dL 188.8 (67.4) 195.3 (72.0) — — —
Min:max 91:577 81:427 — — —
LS mean (SE) change from baseline, % 252.2 (2.0) 217.1 (2.0) 235.1 (2.8) 240.7 to 229.5 ,.0001
Key secondary lipid parameters, mean (SE) n 5 126 n 5 122
LDL-C (baseline–wk 12, ITT) 247.0 (1.9) 215.6 (2.0) 231.5 (2.7) 236.9 to 226.1 ,.0001
Apolipoprotein B (baseline–wk 24, ITT) 236.3 (1.7) 211.2 (1.7) 225.1 (2.4) 229.8 to 220.4 ,.0001
Apolipoprotein B (baseline–wk 24, on-treatment) 242.6 (1.3) 214.4 (1.4) 228.2 (1.9) 232.1 to 224.4 ,.0001
Non–HDL-C (baseline–wk 24, ITT) 240.2 (1.7) 214.6 (1.7) 225.6 (2.4) 230.4 to 220.8 ,.0001
Non–HDL-C (baseline–wk 24, on treatment) 246.9 (1.4) 217.1 (1.5) 229.8 (2.0) 233.9 to 225.8 ,.0001
Total cholesterol (baseline–wk 24, ITT) 231.8 (1.4) 210.9 (1.4) 220.8 (1.9) 224.7 to 217.0 ,.0001
Lipoprotein(a) (baseline–wk 24, ITT) 225.9 (2.4) 27.3 (2.5) 218.7 (3.5) 25.5 to 211.8 ,.0001
HDL-C (baseline–wk 24, ITT)‡ 7.7 (1.7) 6.8 (1.7) 0.9 (2.4) 23.8 to 5.6 .70
Fasting triglycerides (baseline–wk 24, ITT) 29.3 (2.7) 23.6 (2.8) 25.7 (3.9) 213.3 to 1.9 .14
Apolipoprotein A1 (baseline–wk 24, ITT) 4.8 (1.2) 2.9 (1.2) 1.9 (1.7) 21.5 to 5.3 .28
CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares;
SD, standard deviation; SE, standard error.
*Alirocumab 75 mg subcutaneous every 2 weeks (Q2W) with a dose increase to 150 mg Q2W at week 12 depending on week 8 LDL-C values.
†10 mg/d oral ezetimibe.
‡Hierarchical testing terminated at the end point of HDL-C (baseline–week 24, ITT), and this statistical comparison and all subsequent ones were not
considered statistically significant.
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(7.3%), muscle spasms (7.3%), and back pain (5.6%) in
the ezetimibe arm; and myalgia (27.0%), muscle spasms
(11.1%), arthralgia (7.9%), fatigue (7.9%), back pain
(7.9%), headache (6.3%), muscular weakness (6.3%),
paresthesia (6.3%), and vomiting (6.3%) in the atorvastatin
arm. One nonfatal myocardial infarction occurred in the
alirocumab arm.
None of the patients experienced 2 consecutive LDL-C
measurements of ,25 mg/dL (,0.6 mmol/L). Fourteen of
the 16 patients with myalgia in the atorvastatin arm
discontinued treatment, of which 13 entered the open-
label treatment period (including the patient on atorvastatin
who developed myositis) and were further monitored.
Open-label treatment period
The mean (SD) duration of exposure to alirocumab during
the open-label treatment period at the time of this analysiswas
41.2 (11.3) weeks (range 2.0–78.1 weeks). Nearly four-fifths
(79.0%) of the patients reported experiencing an AE: 4.6%
reported an event leading to treatment discontinuation; and
24.2% reported a skeletal muscle–related AE, of which 2.1%
discontinued medication as a consequence (Supplemental
Table 5). One (0.4%) patient died.Discussion
In patients at moderate-to-high cardiovascular risk who
had reported intolerance to 2 or more statins in the past,
self-administered alirocumab reduced LDL-C by 45.0% vs
baseline, compared with a reduction of 14.6% for ezeti-
mibe, at 24 weeks of treatment, with a difference between
groups of 30.4%. Even greater reductions of LDL-C were
observed with alirocumab in the on-treatment analysis
owing to the number of patients who discontinued study
drug but remained in the study for both treatment arms.
Substantially more patients on alirocumab (41.9%) vs
ezetimibe (4.4%) reached an LDL-C ,70 mg/dL or
,100 mg/dL (depending on cardiovascular risk level).
Although mean baseline LDL-C concentration was very
high (191.3 mg/dL), as anticipated in this population, half
of the patients on alirocumab achieved the prespecified
LDL-C concentrations without an increase in dose. Alir-
ocumab was associated with a significantly lower rate of
musculoskeletal AEs vs atorvastatin.
Statins are currently the most effective treatment for
hypercholesterolemia, reducing LDL-C by 30% to 50%1 vs
15% to 20% with non-statin therapies.20 However, statin-
associated muscle symptoms, estimated to affect between
Table 3 Treatment-emergent AEs* and laboratory parameters (safety population) at 24 weeks
AE category or laboratory parameter
Alirocumab†
(n 5 126)
Ezetimibe‡
(n 5 124)
Atorvastatinx
(n 5 63)
Any AE, n (%) 104 (82.5) 100 (80.6) 54 (85.7)
Serious AE,k n (%) 12 (9.5) 10 (8.1) 7 (11.1)
AE leading to death, n (%) 0 0 0
AE leading to treatment discontinuation, n (%) 23 (18.3) 31 (25.0) 16 (25.4)
Skeletal muscle–related AE,{ n (%) 41 (32.5) 51 (41.1) 29 (46.0)
Skeletal muscle–related AE{ leading to treatment discontinuation, n (%) 20 (15.9) 25 (20.2) 14 (22.2)
Musculoskeletal events occurring in $5% of patients in any group, n (%)
Myalgia 31 (24.6) 29 (23.4) 17 (27.0)
Arthralgia 7 (5.6) 9 (7.3) 5 (7.9)
Back pain 5 (4.0) 7 (5.6) 5 (7.9)
Muscle spasms 5 (4.0) 9 (7.3) 7 (11.1)
Muscular weakness 1 (0.8) 2 (1.6) 4 (6.3)
Injection-site reaction 6 (4.8) 6 (4.8) 1 (1.6)
Adjudicated cardiovascular events,# n (%) 4 (3.2) 1 (0.8) 1 (1.6)
Nonfatal myocardial infarction 1 (0.8) 0 0
Ischemia-driven coronary revascularization procedure 3 (2.4) 1 (0.8) 1 (1.6)
Laboratory parameters, n/N (%)
Alanine aminotransferase .3 ! ULN 0 0 0
Creatine kinase .3 ! ULN 3/126 (2.4) 2/123 (1.6) 3/62 (4.8)
AE, adverse event; ULN, upper limit of normal.
*Treatment-emergent AEs are AEs that developed, worsened, or became serious during the AE period (defined as the time from the first dose of
double-blind study treatment to the last injection plus 70 days [10 weeks], as residual effect of alirocumab was expected until 10 weeks after last
injection).
†Alirocumab 75 mg subcutaneous every 2 weeks (Q2W) with a dose increase to 150 mg Q2W at week 12 depending on week 8 low-density lipoprotein
cholesterol values.
‡10 mg/d oral ezetimibe.
x20 mg/d oral atorvastatin (statin rechallenge arm).
kAE resulting in death, is life threatening, requiring hospitalization, resulting in significant disability or incapacity, resulting in a congenital anomaly
or birth defection, or is an important medical event.
{Predefined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness, and muscle fatigue.
#Including coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, unstable angina requiring hospitalization,
congestive heart failure requiring hospitalization, and ischemia-driven coronary revascularization.
766 Journal of Clinical Lipidology, Vol 9, No 6, December 20157% and 29% of patients in clinical practice,5,8 present a ma-
jor limitation to the management of hypercholesterolemia.8
The statin-intolerant population comprises a heterogeneous
group9 and the definitions used are variable8; hence, the
proportion of patients with statin intolerance that is recog-
nizable with blinded, randomized rechallenge isAtorvastatin
Ezetimibe
Alirocumab
HR ALI vs ATV = 0.61 (95% Cl 0.38 to 0.99), nominal P = 0.042
HR ALI vs EZE = 0.71 (95% Cl 0.47 to 1.06), nominal P = 0.096C
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Figure 4 Kaplan–Meier estimates for time to first skeletal
muscle–related AE (predefined as myalgia, muscle spasms,
muscular weakness, musculoskeletal stiffness, or muscle fatigue).
AE, adverse event; ALI, alirocumab; ATV, atorvastatin; CI, confi-
dence interval; EZE, ezetimibe; HR, hazard ratio.unknown.6,7 The present study recruited patients with a
documented history of intolerance to at least 2 statins
(including 1 at the lowest recommended daily starting
dose). The presence of intolerance was carefully scrutinized
through the novel trial design, which incorporated a pla-
cebo run-in phase to exclude patients who experienced
symptoms in the absence of statin therapy, and a statin re-
challenge arm to document the rate of reproducible statin
intolerance.
Over the 4-week placebo run-in, 6.4% of the screened
patients failed to qualify for the double-blind treatment,
suggesting that some patients may experience muscle
symptoms because of negative expectations surrounding
the potential for statin treatment or for reasons unrelated to
statin therapy. During the 24-week double-blind treatment
period, 46.0% of patients reported skeletal muscle AEs
when rechallenged with atorvastatin 20 mg, a dose judged
sufficient to elicit statin-related muscle symptoms, while
not preventing patients from consenting to participate in the
study,21 and 22.2% discontinued atorvastatin as a conse-
quence. The discontinuation rate may have increased with
more prolonged use, as reported elsewhere.25 This rate of
Moriarty et al Alirocumab in statin-intolerant patients 767discontinuations is consistent with the Cleveland Clinic
experience, which reported a rate of 27.5%, in which
72.5% of patients with statin intolerance were able to
tolerate a subsequent trial of statin therapy.26 As such, we
have documented in a prospective randomized blinded
study that many patients with a history of statin intolerance
actually ‘‘can’’ tolerate a statin.
In the present study, alirocumab-treated patients experi-
enced a lower rate of muscle-related AEs vs atorvastatin
and showed a trend toward a lower rate vs ezetimibe. The
notable rate of skeletal muscle–related AEs in all treatment
groups in this study may be related to the novel definition
used, namely myalgia, muscle spasms, muscular weakness,
musculoskeletal stiffness, and muscle fatigue. Although
across-trial comparisons have recognized limitations, it is
useful to contrast the rates of myalgia (a common Medical
Dictionary for Regulatory Activities term) in this popula-
tion with those from similar studies. The rate of myalgia in
alirocumab-treated patients was higher in the present study
than in the ODYSSEY MONO study14 (24.6% vs 3.8%,
respectively), with most cases occurring within the first
14 weeks of this 24-week trial; but the rate was also higher
with ezetimibe (23.4% vs 3.9%, respectively), a drug that is
usually well tolerated.27 Similarly, the rates of myalgia
were higher than in the Goal Achievement after Utilizing
an Anti-PCSK9 Antibody in Statin Intolerant Subjects
(GAUSS-2) trial in which patients were randomized to evo-
locumab or ezetimibe (8% with evolocumab and 18% with
ezetimibe).28 However, the study designs and definitions for
statin intolerance differed, and the duration of treatment
was significantly shorter in GAUSS-2 (12 vs 24 weeks).
Furthermore, the absence of a statin rechallenge arm in
GAUSS-2 may have avoided behaviors associated with
negative expectations surrounding possible statin treatment.
During the open-label treatment period of this study
(mean of 41 weeks), when patients knew that they were not
receiving statin therapy, rates of skeletal muscle–related
AEs were substantially lower than those during the double-
blind period (24.2% vs 32.5%, respectively). Similarly,
discontinuations due to skeletal muscle–related AEs were
also lower (2.1% vs 15.9%, respectively). Rates of muscle
symptoms and muscle-related discontinuations in the open-
label treatment period are reasonably consistent with the
overall ODYSSEY program (15.1% and 0.4%, respec-
tively). These findings raise the possibility that this statin-
intolerant population may have been anticipating the
possibility of side effects if rechallenged with a statin
during the double-blind period, expressing behavior learned
in response to prior statin exposure when reporting muscle
symptoms, whether treatment-related or not.
In contrast, the rates of muscle-related AEs in the
atorvastatin arm reinforce the challenges clinicians face
when diagnosing statin intolerance. One would anticipate
that a sizable proportion of statin-intolerant patients would
report a recurrence of symptoms when rechallenged with
atorvastatin 20 mg. It may be, however, that randomized
patients had prior muscle symptoms with a statin other thanatorvastatin or at a higher dose; also, the study duration or
the dose chosen may have been insufficient for symptoms
to manifest in some patients. Furthermore, symptoms in
patients who declined to participate may have been more
severe than in those who agreed. Our study would suggest
that a careful rechallenge of patients with a possible history
of statin intolerance would be warranted, and in those who
truly do have statin intolerance (either from clear prior
documentation or prospective rechallenge), alirocumab
would be a powerful means of lowering their LDL-C.
The mean LDL-C concentration at baseline was
$190 mg/dL, a recognized risk threshold for drug treat-
ment regardless of cardiovascular risk level. As such, these
statin-intolerant patients are unlikely, if taking a less than
optimal statin dose or less-effective non-statin therapies, to
achieve the lipid reductions recommended, or anticipated,
in guidelines.1,20 In the present study, alirocumab was
significantly more effective than ezetimibe at reducing
LDL-C, total cholesterol, non–HDL-C, apolipoprotein B,
and lipoprotein(a). Favorable changes in triglycerides
(decrease of 9.3%) and HDL-C (increase of 7.7%) were
also seen with alirocumab; they did not, however, differ
in comparison to ezetimibe and were within the boundaries
expected.29 The reduction in LDL-C of 31.9% with atorvas-
tatin (although exploratory only) was as expected, given the
dropout rate and ITT approach, which included off-
treatment data.17,30
Study limitations
The study design, which included placebo run-in and
statin rechallenge to confirm statin intolerance, may have
resulted in hypervigilance by study participants regarding
potential statin re-exposure. The definition of statin intol-
erance differs from those used in other reports, and these
results cannot be generalized to all individuals with statin-
associated muscle symptoms, particularly those who refuse
to be rechallenged with a statin and who may have had even
more severe symptoms than the participants. It should also
be noted that the study population was predominantly
white—an aspect that would benefit from being addressed
in future studies. Finally, the study duration was short, and
the rate of treatment discontinuation may increase over the
longer term.
Cardiovascular outcomes with alirocumab are currently
being evaluated in a large ongoing study (http://
clinicaltrials.gov/show/NCT01663402)16 and will be as-
sessed in a pooled analysis from the overall ODYSSEY
program.Conclusions
Alirocumab demonstrated significantly greater LDL-C-
lowering vs ezetimibe after 24 weeks of treatment in a
population with a history of statin intolerance at moderate
to very high cardiovascular risk and with elevated LDL-C
768 Journal of Clinical Lipidology, Vol 9, No 6, December 2015concentrations at baseline. In this population, alirocumab
was well tolerated, with significantly lower rates of
musculoskeletal AEs compared with atorvastatin and a
trend toward lower rates compared with ezetimibe. There
was also a trend toward lower rates of muscular events
leading to treatment discontinuation when compared with
atorvastatin or ezetimibe. More patients achieved LDL-C
goals with alirocumab vs ezetimibe. Accordingly, alirocu-
mab may provide a suitable clinical option in the future
management of patients who are intolerant of statins.Acknowledgment
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